1. JohnsonLF, MossongJ, DorringtonRE, SchomakerM, HoffmannCJ, et al. (2013) Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med 10: e1001418.
2. Lloyd-SmithE, BrodkinE, WoodE, KerrT, TyndallMW, et al. (2006) Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS 20: 445–450.
3. MayM, GompelsM, DelpechV, PorterK, PostF, et al. (2011) Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 343: d6016.
4. SabinCA (2013) Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy? BMC Med 11: 251.
5. FangCT, ChangYY, HsuHM, TwuSJ, ChenKT, et al. (2007) Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM 100: 97–105.
6. LawnSD, FrenchMA (2007) Immune reconstitution disease: recent developments and implications for antiretroviral treatment in resource-limited settings. Curr Opin HIV AIDS 2: 339–345.
7. LawnSD, BekkerLG, MillerRF (2005) Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 5: 361–373.
8. MeintjesG, LawnSD, ScanoF, MaartensG, FrenchMA, et al. (2008) Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 8: 516–523.
9. BreenRA, SmithCJ, BettinsonH, DartS, BannisterB, et al. (2004) Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 59: 704–707.
10. BretonG, DuvalX, EstellatC, PoalettiX, BonnetD, et al. (2004) Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 39: 1709–1712.
11. ZolopaA, AndersenJ, PowderlyW, SanchezA, SanneI, et al. (2009) Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 4: e5575.
12. Abdool KarimSS, NaidooK, GroblerA, PadayatchiN, BaxterC, et al. (2010) Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 362: 697–706.
13. CastelnuovoB, ManabeYC, KiraggaA, KamyaM, EasterbrookP, et al. (2009) Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 49: 965–972.
14. Abdool KarimSS, NaidooK, GroblerA, PadayatchiN, BaxterC, et al. (2011) Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 365: 1492–1501.
15. MahnkeYD, GreenwaldJH, DerSimonianR, RobyG, AntonelliLR, et al. (2012) Selective expansion of polyfunctional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood 119: 3105–3112.
16. AntonelliLR, MahnkeY, HodgeJN, PorterBO, BarberDL, et al. (2010) Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood 116: 3818–3827.
17. BarberDL, AndradeBB, SeretiI, SherA (2012) Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat Rev Microbiol 10: 150–156.
18. BourgaritA, CarcelainG, MartinezV, LascouxC, DelceyV, et al. (2006) Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 20: F1–7.
19. MeintjesG, SkolimowskaKH, WilkinsonKA, MatthewsK, TadokeraR, et al. (2012) Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 186: 369–377.
20. TadokeraR, MeintjesG, SkolimowskaKH, WilkinsonKA, MatthewsK, et al. (2011) Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur Respir J 37: 1248–1259.
21. ConradieF, FoulkesAS, IveP, YinX, RoussosK, et al. (2011) Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr 58: 309–318.
22. LawnSD, MeintjesG (2011) Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther 9: 415–430.
23. TranHT, Van den BerghR, VuTN, LaukensK, WorodriaW, et al. (2014) The role of monocytes in the development of Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome. Immunobiology 219: 37–44.
24. TranHT, Van den BerghR, LoembeMM, WorodriaW, Mayanja-KizzaH, et al. (2013) Modulation of the complement system in monocytes contributes to tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 27: 1725–1734.
25. MaraisS, MeintjesG, PepperDJ, DoddLE, SchutzC, et al. (2013) Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis 56: 450–460.
26. GopalanN, AndradeBB, SwaminathanS (2014) Tuberculosis-immune reconstitution inflammatory syndrome in HIV: from pathogenesis to prediction. Expert Rev Clin Immunol 10: 631–645.
27. BarberDL, Mayer-BarberKD, AntonelliLR, WilsonMS, WhiteS, et al. (2010) Th1-driven immune reconstitution disease in Mycobacterium avium-infected mice. Blood 116: 3485–3493.
28. BarberDL, AndradeBB, McBerryC, SeretiI, SherA (2014) Role of IL-6 in Mycobacterium avium–associated immune reconstitution inflammatory syndrome. J Immunol 192: 676–682.
29. ShiC, PamerEG (2011) Monocyte recruitment during infection and inflammation. Nat Rev Immunol 11: 762–774.
30. NarendranG, AndradeBB, PorterBO, ChandrasekharC, VenkatesanP, et al. (2013) Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction. PLoS One 8: e63541.
31. van der PlasH, MeintjesG, SchutzC, GoliathR, MyerL, et al. (2013) Complications of antiretroviral therapy initiation in hospitalised patients with HIV-associated tuberculosis. PLoS One 8: e54145.
32. Conesa-BotellaA, MeintjesG, CoussensAK, van der PlasH, GoliathR, et al. (2012) Corticosteroid therapy, vitamin D status, and inflammatory cytokine profile in the HIV-tuberculosis immune reconstitution inflammatory syndrome. Clin Infect Dis 55: 1004–1011.
33. Conesa-BotellaA, LoembeMM, ManabeYC, WorodriaW, MazakpweD, et al. (2011) Urinary lipoarabinomannan as predictor for the tuberculosis immune reconstitution inflammatory syndrome. J Acquir Immune Defic Syndr 58: 463–468.
34. HerbeinG, VarinA (2010) The macrophage in HIV-1 infection: from activation to deactivation? Retrovirology 7: 33.
35. SchlugerNW (2005) The pathogenesis of tuberculosis: the first one hundred (and twenty-three) years. Am J Respir Cell Mol Biol 32: 251–256.
36. BurdoTH, LoJ, AbbaraS, WeiJ, DeLelysME, et al. (2011) Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 204: 1227–1236.
37. KnudsenTB, GustafsonP, KronborgG, KristiansenTB, MoestrupSK, et al. (2005) Predictive value of soluble haemoglobin scavenger receptor CD163 serum levels for survival in verified tuberculosis patients. Clin Microbiol Infect 11: 730–735.
38. SandlerNG, WandH, RoqueA, LawM, NasonMC, et al. (2011) Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 203: 780–790.
39. BakerJV, Huppler HullsiekK, BradfordRL, ProsserR, TracyRP, et al. (2013) Circulating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patients. J Acquir Immune Defic Syndr 63: 367–371.
40. MayneE, FunderburgNT, SiegSF, AsaadR, KalinowskaM, et al. (2012) Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. J Acquir Immune Defic Syndr 59: 340–346.
41. SuGL, SimmonsRL, WangSC (1995) Lipopolysaccharide binding protein participation in cellular activation by LPS. Crit Rev Immunol 15: 201–214.
42. OsterudB (2012) Tissue factor/TFPI and blood cells. Thromb Res 129: 274–278.
43. KothariH, RaoLV, VankayalapatiR, PendurthiUR (2012) Mycobacterium tuberculosis infection and tissue factor expression in macrophages. PLoS One 7: e45700.
44. Skrzeczynska-MoncznikJ, BzowskaM, LosekeS, Grage-GriebenowE, ZembalaM, et al. (2008) Peripheral blood CD14high CD16+ monocytes are main producers of IL-10. Scand J Immunol 67: 152–159.
45. BelgeKU, DayyaniF, HoreltA, SiedlarM, FrankenbergerM, et al. (2002) The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 168: 3536–3542.
46. CrosJ, CagnardN, WoollardK, PateyN, ZhangSY, et al. (2010) Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 33: 375–386.
47. DhimanR, BandaruA, BarnesPF, SahaS, TvinnereimA, et al. (2011) c-Maf-dependent growth of Mycobacterium tuberculosis in a CD14(hi) subpopulation of monocyte-derived macrophages. J Immunol 186: 1638–1645.
48. MendoncaVR, QueirozAT, LopesFM, AndradeBB, Barral-NettoM (2013) Networking the host immune response in Plasmodium vivax malaria. Malar J 12: 69.